{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:51:29Z","timestamp":1791341489498,"version":"4.3.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010665","name":"EU Framework Programme for Research and Innovation Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["956185"],"award-info":[{"award-number":["956185"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","award":["W.OB21-01"],"award-info":[{"award-number":["W.OB21-01"]}],"id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009629","name":"Trento and Rovereto Bank Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009629","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013428","name":"Muscles for Muscles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.omtm.2024.101379","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T09:08:33Z","timestamp":1731488913000},"page":"101379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Patient-specific responses to SMN2 splice-modifying treatments in spinal muscular atrophy fibroblasts"],"prefix":"10.1016","volume":"32","author":[{"given":"Ilaria","family":"Signoria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria M.","family":"Zwartkruis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte","family":"Geerlofs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Perenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiterie M.E.","family":"Faller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"McHale-Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared W.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Kortooms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie H.","family":"Snellen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fay-Lynn","family":"Asselman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Gillingwater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Viero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renske I.","family":"Wadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Ludo","family":"van der Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2330-9444","authenticated-orcid":false,"given":"Ewout J.N.","family":"Groen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2024.101379_bib1","article-title":"Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine","volume":"2","author":"Chaytow","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.omtm.2024.101379_bib2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","article-title":"Spinal muscular atrophy","volume":"8","author":"Mercuri","year":"2022","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.omtm.2024.101379_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2024.101379_bib4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/jnnp-2016-314292","article-title":"Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0\u20134","volume":"88","author":"Wadman","year":"2017","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.omtm.2024.101379_bib5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","article-title":"Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases","volume":"28","author":"Calucho","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtm.2024.101379_bib6","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"Monani","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2024.101379_bib7","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2024.101379_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024269","article-title":"Utility of\u00a0Survival Motor Neuron ELISA for Spinal Muscular Atrophy Clinical and Preclinical Analyses","volume":"6","author":"Kobayashi","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2024.101379_bib9","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/hmg\/ddy195","article-title":"Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy","volume":"27","author":"Groen","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2024.101379_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167087","article-title":"A Comparative Study of SMN Protein and mRNA in Blood and Fibroblasts in Patients with Spinal Muscular Atrophy and Healthy Controls","volume":"11","author":"Wadman","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2024.101379_bib11","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1172\/JCI124120","article-title":"Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment","volume":"129","author":"Ramos","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2024.101379_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150640","article-title":"SMN Protein Can Be Reliably Measured in Whole Blood with an Electrochemiluminescence (ECL) Immunoassay: Implications for Clinical Trials","volume":"11","author":"Zaworski","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2024.101379_bib13","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2024.101379_bib14","doi-asserted-by":"crossref","first-page":"35ra42","DOI":"10.1126\/scitranslmed.3000830","article-title":"Systemic Delivery of scAAV9 Expressing SMN Prolongs Survival in a Model of Spinal Muscular Atrophy","volume":"2","author":"Valori","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2024.101379_bib15","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2024.101379_bib16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2024.101379_bib17","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajhg.2008.01.014","article-title":"Antisense Masking of an hnRNP A1\/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice","volume":"82","author":"Hua","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2024.101379_bib18","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1126\/science.1250127","article-title":"Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy","volume":"345","author":"Naryshkin","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.omtm.2024.101379_bib19","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in Type 1 Spinal Muscular Atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2024.101379_bib20","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2024.101379_bib84","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","article-title":"Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2024.101379_bib21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.27853","article-title":"Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study","volume":"68","author":"Crawford","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtm.2024.101379_bib22","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","article-title":"Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis","volume":"16","author":"Coratti","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omtm.2024.101379_bib23","first-page":"2531","article-title":"Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)","volume":"270","author":"Oskoui","year":"2023","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.omtm.2024.101379_bib24","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1007\/s12325-024-02845-6","article-title":"Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy","volume":"41","author":"Kokaliaris","year":"2024","journal-title":"Adv. Ther."},{"key":"10.1016\/j.omtm.2024.101379_bib25","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/gt.2017.34","article-title":"How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy","volume":"24","author":"Singh","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2024.101379_bib26","article-title":"The First Orally Deliverable Small Molecule for the Treatment of Spinal Muscular Atrophy","volume":"15","author":"Singh","year":"2020","journal-title":"J.\u00a0Exp. Neurosci."},{"key":"10.1016\/j.omtm.2024.101379_bib27","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/15592294.2019.1626651","article-title":"Human aging DNA methylation signatures are conserved but accelerated in cultured fibroblasts","volume":"14","author":"Sturm","year":"2019","journal-title":"Epigenetics"},{"key":"10.1016\/j.omtm.2024.101379_bib28","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.devcel.2024.05.011","article-title":"Identifying FUS amyotrophic lateral sclerosis disease signatures in patient dermal fibroblasts","volume":"59","author":"Kumbier","year":"2024","journal-title":"Dev. Cell"},{"key":"10.1016\/j.omtm.2024.101379_bib29","doi-asserted-by":"crossref","first-page":"fcaa075","DOI":"10.1093\/braincomms\/fcaa075","article-title":"Intragenic and structural variation in the SMN locus and clinical variability in spinal muscular atrophy","volume":"2","author":"Wadman","year":"2020","journal-title":"Brain Commun."},{"key":"10.1016\/j.omtm.2024.101379_bib30","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.3390\/cells11172624","article-title":"The Proteome Signatures of\u00a0Fibroblasts from Patients with Severe, Intermediate and Mild Spinal Muscular Atrophy Show Limited Overlap","volume":"11","author":"Brown","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.omtm.2024.101379_bib31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43856-024-00515-w","article-title":"Altered mitochondrial function in fibroblast cell lines derived from disease carriers of spinal muscular atrophy","volume":"4","author":"James","year":"2024","journal-title":"Commun. Med."},{"key":"10.1016\/j.omtm.2024.101379_bib32","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202317683","article-title":"PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice","volume":"15","author":"Kordala","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtm.2024.101379_bib33","doi-asserted-by":"crossref","first-page":"fcac269","DOI":"10.1093\/braincomms\/fcac269","article-title":"Population-based assessment of nusinersen efficacy in children with spinal muscular atrophy: a 3-year follow-up study","volume":"4","author":"Scheijmans","year":"2022","journal-title":"Brain Commun."},{"key":"10.1016\/j.omtm.2024.101379_bib34","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s12015-019-09910-6","article-title":"Spinal Muscular Atrophy Modeling and Treatment Advances by Induced Pluripotent Stem Cells Studies","volume":"15","author":"Adami","year":"2019","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.omtm.2024.101379_bib35","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1093\/nar\/gkad259","article-title":"Diverse targets of SMN2-directed splicing-modulating small molecule therapeutics for spinal muscular atrophy","volume":"51","author":"Ottesen","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2024.101379_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109125","article-title":"A high-throughput genome-wide RNAi screen identifies modifiers of survival motor neuron protein","volume":"35","author":"McCormack","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtm.2024.101379_bib37","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/hmg\/dds437","article-title":"VPA response in SMA is suppressed by the fatty acid translocase CD36","volume":"22","author":"Garbes","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2024.101379_bib40","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/MCB.06077-11","article-title":"A Role for SMN Exon 7 Splicing in the Selective Vulnerability of Motor Neurons in Spinal Muscular Atrophy","volume":"32","author":"Ruggiu","year":"2012","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.omtm.2024.101379_bib38","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/jnc.14935","article-title":"Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells","volume":"153","author":"Pagliarini","year":"2020","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.omtm.2024.101379_bib39","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1093\/nar\/gkad1259","article-title":"A super minigene with a short promoter and truncated introns recapitulates essential features of transcription and splicing regulation of the SMN1 and SMN2 genes","volume":"52","author":"Ottesen","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2024.101379_bib41","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1038\/ncomms7626","article-title":"Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells","volume":"6","author":"Du","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2024.101379_bib42","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nature07677","article-title":"Induced pluripotent stem cells from a spinal muscular atrophy patient","volume":"457","author":"Ebert","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2024.101379_bib43","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00018-022-04450-8","article-title":"Moxifloxacin rescues SMA phenotypes in patient-derived cells and animal model","volume":"79","author":"Januel","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omtm.2024.101379_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/srep11696","article-title":"Decay in survival motor neuron and plastin 3 levels during differentiation of iPSC-derived human motor neurons","volume":"5","author":"Boza-Mor\u00e1n","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2024.101379_bib45","doi-asserted-by":"crossref","first-page":"15662","DOI":"10.1074\/jbc.M115.646257","article-title":"Gemin5 Binds to the Survival Motor Neuron mRNA to Regulate SMN Expression","volume":"290","author":"Workman","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2024.101379_bib46","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.3390\/cells9112405","article-title":"A\u00a0Single Amino Acid Residue Regulates PTEN-Binding and Stability of the Spinal Muscular Atrophy Protein SMN","volume":"9","author":"Rademacher","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.omtm.2024.101379_bib47","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00018-022-04522-9","article-title":"The phospho-landscape of the survival of motoneuron protein (SMN) protein: relevance for spinal muscular atrophy (SMA)","volume":"79","author":"Detering","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.omtm.2024.101379_bib48","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/s41593-021-00827-3","article-title":"Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit","volume":"24","author":"Van Alstyne","year":"2021","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.omtm.2024.101379_bib49","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s44321-024-00037-x","article-title":"Improved gene therapy for spinal muscular atrophy in mice using codon-optimized hSMN1 transgene and hSMN1 gene-derived promotor","volume":"16","author":"Xie","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtm.2024.101379_bib50","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s44321-024-00036-y","article-title":"Promoting expression in gene therapy: more is not always better","volume":"16","author":"Zwartkruis","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtm.2024.101379_bib51","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87908","article-title":"Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy","volume":"1","author":"Powis","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtm.2024.101379_bib52","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1172\/JCI71318","article-title":"Dysregulation of ubiquitin homeostasis and \u03b2-catenin signaling promote spinal muscular atrophy","volume":"124","author":"Wishart","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2024.101379_bib53","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1126\/science.1155085","article-title":"Plastin 3 Is a Protective Modifier of Autosomal Recessive Spinal Muscular Atrophy","volume":"320","author":"Oprea","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.omtm.2024.101379_bib54","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ajhg.2016.07.014","article-title":"The Power of Human Protective Modifiers: PLS3 and CORO1C Unravel Impaired Endocytosis in Spinal Muscular Atrophy and Rescue SMA Phenotype","volume":"99","author":"Hosseinibarkooie","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2024.101379_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033572","article-title":"Evaluation of SMN Protein, Transcript, and Copy Number in the Biomarkers for Spinal Muscular Atrophy (BforSMA) Clinical Study","volume":"7","author":"Crawford","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2024.101379_bib56","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s42003-021-02116-y","article-title":"DNA methylation changes during long-term in\u00a0vitro cell culture are caused by epigenetic drift","volume":"4","author":"Franzen","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.omtm.2024.101379_bib57","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.molmed.2012.11.002","article-title":"Spinal muscular atrophy: going beyond the motor neuron","volume":"19","author":"Hamilton","year":"2013","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.omtm.2024.101379_bib58","doi-asserted-by":"crossref","first-page":"35375","DOI":"10.1021\/acsomega.1c04688","article-title":"Spinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Display Altered Proteomes at Early Stages of Differentiation","volume":"6","author":"Varderidou-Minasian","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.omtm.2024.101379_bib59","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1089\/scd.2018.0181","article-title":"A SMN2 Splicing Modifier Rescues the Disease Phenotypes in an In\u00a0Vitro Human Spinal Muscular Atrophy Model","volume":"28","author":"Son","year":"2019","journal-title":"Stem Cell. Dev."},{"key":"10.1016\/j.omtm.2024.101379_bib60","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13395-020-00232-7","article-title":"SMN-deficiency disrupts SERCA2 expression and intracellular Ca2+ signaling in cardiomyocytes from SMA mice and patient-derived iPSCs","volume":"10","author":"Khayrullina","year":"2020","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtm.2024.101379_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2023.103095","article-title":"Generation of two induced pluripotent stem cell lines from spinal muscular atrophy type 1 patients carrying no functional copies of SMN1 gene","volume":"69","author":"Zeng","year":"2023","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.omtm.2024.101379_bib62","doi-asserted-by":"crossref","DOI":"10.1038\/srep11746","article-title":"Spinal muscular atrophy phenotype is ameliorated in human motor neurons by SMN increase via different novel RNA therapeutic approaches","volume":"5","author":"Nizzardo","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtm.2024.101379_bib63","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/hmg\/6.8.1205","article-title":"The Survival Motor Neuron Protein in Spinal Muscular Atrophy","volume":"6","author":"Coovert","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2024.101379_bib64","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1073\/pnas.0633863100","article-title":"Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts","volume":"100","author":"Skordis","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2024.101379_bib65","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.neuron.2016.11.033","article-title":"The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy","volume":"93","author":"d\u2019Ydewalle","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.omtm.2024.101379_bib66","article-title":"Activating ATF6 in spinal muscular atrophy promotes SMN expression and motor neuron survival through the IRE1\u03b1-XBP1 pathway","volume":"48","author":"D\u2019Amico","year":"2022","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.omtm.2024.101379_bib67","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.stem.2015.08.003","article-title":"Genome-wide RNA-Seq of Human Motor Neurons Implicates Selective ER Stress Activation in Spinal Muscular Atrophy","volume":"17","author":"Ng","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.omtm.2024.101379_bib68","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1242\/dmm.021766","article-title":"Abnormal mitochondrial transport and morphology as early pathological changes in human models of spinal muscular atrophy","volume":"9","author":"Xu","year":"2016","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.omtm.2024.101379_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810878","article-title":"Mitochondrial Dysfunction in Spinal Muscular Atrophy","volume":"23","author":"Zilio","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2024.101379_bib70","article-title":"Spinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Have Reduced Expression of Proteins Important in Neuronal Development","volume":"9","author":"Fuller","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.omtm.2024.101379_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105366","article-title":"Intracellular pathways involved in cell survival are deregulated in mouse and human spinal muscular atrophy motoneurons","volume":"155","author":"Sansa","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.omtm.2024.101379_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039113","article-title":"Inhibition of Apoptosis Blocks Human Motor Neuron Cell Death in a Stem Cell Model of Spinal Muscular Atrophy","volume":"7","author":"Sareen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2024.101379_bib73","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.050352","article-title":"Innovating spinal muscular atrophy models in the therapeutic era","volume":"16","author":"Signoria","year":"2023","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.omtm.2024.101379_bib74","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1474-4422(23)00419-2","article-title":"Challenges and opportunities in spinal muscular atrophy therapeutics","volume":"23","author":"Yeo","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtm.2024.101379_bib75","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jcf.2023.03.004","article-title":"FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes","volume":"22","author":"de Poel","year":"2023","journal-title":"J.\u00a0Cyst. Fibros."},{"key":"10.1016\/j.omtm.2024.101379_bib76","doi-asserted-by":"crossref","first-page":"344ra84","DOI":"10.1126\/scitranslmed.aad8278","article-title":"Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis","volume":"8","author":"Dekkers","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omtm.2024.101379_bib77","doi-asserted-by":"crossref","first-page":"e1634","DOI":"10.1212\/WNL.0000000000009248","article-title":"Population-based analysis of survival in spinal muscular atrophy","volume":"94","author":"Wijngaarde","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2024.101379_bib78","doi-asserted-by":"crossref","first-page":"e1988","DOI":"10.1212\/WNL.0000000000010540","article-title":"Muscle strength and motor function in adolescents and adults with spinal muscular atrophy","volume":"95","author":"Wijngaarde","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2024.101379_bib79","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","article-title":"Childhood spinal muscular atrophy: controversies and challenges","volume":"11","author":"Mercuri","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtm.2024.101379_bib80","doi-asserted-by":"crossref","DOI":"10.1177\/26331055241233596","article-title":"Synergistic Effect of an Antisense Oligonucleotide and Small Molecule on Splicing Correction of the Spinal Muscular Atrophy Gene","volume":"19","author":"Ottesen","year":"2024","journal-title":"Neurosci. Insights"},{"key":"10.1016\/j.omtm.2024.101379_bib81","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3390\/genes13040685","article-title":"High Concentration or Combined Treatment of Antisense Oligonucleotides for Spinal Muscular Atrophy Perturbed SMN2 Splicing in Patient Fibroblasts","volume":"13","author":"Wijaya","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.omtm.2024.101379_bib82","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/s41467-017-01559-4","article-title":"Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers","volume":"8","author":"Sivaramakrishnan","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2024.101379_bib83","first-page":"e59438","article-title":"Robust Comparison of Protein Levels Across Tissues and Throughout Development Using Standardized Quantitative Western Blotting","volume":"146","author":"Huang","year":"2019","journal-title":"J. Vis. Exp."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050124001955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050124001955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:56:14Z","timestamp":1778867774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050124001955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2329050124001955"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2024.101379","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.07.24.604892","asserted-by":"object"}]},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-specific responses to SMN2 splice-modifying treatments in spinal muscular atrophy fibroblasts","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2024.101379","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101379"}}